Engineered mucoadhesive microparticles of formoterol/budesonide for pulmonary administration

Eur J Pharm Sci. 2021 Oct 1:165:105955. doi: 10.1016/j.ejps.2021.105955. Epub 2021 Jul 21.

Abstract

In the present study, a multi-component system comprised of dipalmitylphospatidylcholine (DPPC), Chitosan, Lactose, and L-Leucine was developed for pulmonary delivery. Microparticles were engineered by the spray drying process and the selection of the critical parameters was performed by applying experimental design. The microcarriers with the appropriate size and yield were co-formulated with two active pharmaceutical ingredients (APIs), namely, Formoterol fumarate and Budesonide, and they were further investigated. All formulations exhibited spherical shape, appropriate aerodynamic performance, satisfying entrapment efficiency, and drug load. Their physicochemical properties were evaluated using Scanning Electron Microscopy (SEM), Fourier Transform Infrared Spectroscopy (FT-IR), and Differential Scanning Calorimetry (DSC). The aerodynamic particle size characterization was determined using an eight-stage Andersen cascade impactor, whereas the release of the actives was monitored in vitro in simulated lung fluid. Additional evaluation of the microparticles' mucoadhesive properties was performed by ζ-potential measurements and ex vivo mucoadhesion study applying a falling liquid film method using porcine lung tissue. Cytotoxicity and cellular uptake studies in Calu-3 lung epithelial cell line were conducted to further investigate the safety and efficacy of the developed formulations.

Keywords: Budesonide; Formoterol; Mucoadhesion; Pulmonary delivery; Spray drying.

MeSH terms

  • Administration, Inhalation
  • Animals
  • Budesonide*
  • Calorimetry, Differential Scanning
  • Drug Compounding
  • Formoterol Fumarate
  • Microscopy, Electron, Scanning
  • Particle Size
  • Spectroscopy, Fourier Transform Infrared
  • Swine

Substances

  • Budesonide
  • Formoterol Fumarate